Expression of platelet-derived growth factor-alpha receptor in human osteosarcoma is not a predictor of outcome

References

• Dorfman HD, Czerniak B. Osteosarcoma. In: Bone Tumours. 1st ed, Dorfman HD, Czerniak B, editors. St Louis: Mosby, 1998; 128–252.
   Google Scholar
• Bielack S, Jürgens H, Jundt G, et al Osteosarcoma: The COSS experience. Cancer Treat Res 2010; 152: 289–308.
   Google Scholar
• Mankin HJ, Hornicek FJ, Rosenberg AE, et al Survival data for 648 patients with osteosarcoma treated at one institution. Clin Orthop Relat Res 2004; 429: 286–91.
   Google Scholar
• Kaste SC, Liu T, Billups CA, et al Tumour size as a predictor of outcome in pediatric non- metastatic osteosarcoma of the extremity. Pediatr Blood Cancer 2004; 43: 723–8.
   Google Scholar
• Fellenberg J, Krauthoff A, Pollandt K, et al Evaluation of the predictive value of Her-2/neu gene expression on osteosarcoma therapy in laser-microdissected paraffin-embedded tissue. Lab Invest 2004; 84: 113–21.
   Google Scholar
• Tsai JY, Aviv H, Benevenia J, et al HER-2/neu and p53 in osteosarcoma: an immunohistochemical and fluorescence in situ hybridization analysis. Cancer Invest 2004; 22: 16–24.
   Google Scholar
• Wunder JS, Gokgoz N, Parkes R, et al TP53 mutations and outcome in osteosarcoma: a predictive, multicenter study. J Clin Oncol 2005; 23: 1483–90.
   Google Scholar
• Mintz MB, Sowers R, Brown KM, et al An expression signature classifies chemotherapy-resistant pediatric osteosarcoma. Cancer Res 2005; 65: 1748–54.
   Google Scholar
• Sulzbacher I, Träxler M, Mosberger I, et al Platelet-derived growth factor-AA and -α receptor expression suggests an autocrine and/or paracrine loop in osteosarcoma. Mod Pathol 2000; 13: 632–37.
   Google Scholar
• Sulzbacher I, Birner P, Trieb K, et al Expression of Platelet-Derived Growth Factor-AA is associated with tumour progression in osteosarcoma. Mod Pathol 2003; 16: 66–71.
   Google Scholar
• Corless CL, Schroeder A, Griffith D, et al PDGFRA mutations in gastrointestinal stromal tumours: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 2005; 23: 5357–64.
   Google Scholar
• de Mestier P, des Guetz G. Treatment of gastrointestinal stroma tumors with imatinib mesylate: a major breakthrough in the understanding of tumour-specific molecular characteristics. World J Surg 2005; 29: 357–61.
   Google Scholar
• Debiec-Rychter M, Dumez H, Judson I, et al Use of c-KIT/PDGFRA mutation analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2004; 40: 689–95.
   Google Scholar
• Kubo T, Piperdi S, Rosenblum J, et al Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma. Cancer 2008; 112: 2119–29.
   Google Scholar
• Salzer-Kuntschik M, Brand G, Delling G. Determination of the degree of morphological regression following chemotherapy in malignant bone tumours. Pathologe 1983; 4: 135–41.
   PubMed Web of Science ®Google Scholar
• McGary EC, Weber K, Mills L, et al Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571. Clin Cancer Res 2002; 8: 3584–91.
   Google Scholar
• Bond M, Bernstein ML, Pappo A, et al A phase II study of imatinib mesylate in children with refractory or relapsed solid tumours: a Children'S Oncology Group study. Pediatr Blood Cancer 2008; 50: 254–8.
   Google Scholar
• Wang LF, Zhou Y, Xu YM, et al A caspase-6 and anti-HER2 antibody chimeric tumour-targeted proapoptotic molecule decreased metastasis of human osteosarcoma. Cancer Invest 2009; 27: 774–80.
   Google Scholar
• Scotlandi K, Picci P. Targeting insulin like growth factor 1 receptor in sarcomas. Curr Opin Oncol 2008; 20: 419–27.
   Google Scholar
• Kim SY, Toretsky JA, Scher D, et al The role of IGF-1R in pediatric malignancies. Oncologist 2009, 14: 83–91.
   PubMed Web of Science ®Google Scholar
• Haluska P, Shaw HM, Natzel GN, et al Phase I dose escalation study of the anti insulin-like growth factor I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumours. Clin Cancer Res 2007; 13: 5834–40.
   Google Scholar
• Mita MM, Mita AC, Chu QS, et al Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administrated intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J Clin Oncol 2008; 26: 361–7.
   Google Scholar
• Manara MC, Nicoletti G, Zambelli D, et al NVP-BEZ235 as a new therapeutic option for sarcomas. Clin Cancer Res 2010; 16: 530–40.
   Google Scholar
• Chawla SP, Chua VS, Fernandez L, et al Phase I/II and phase II studies of targeted gene delivery in vivo: Intravenous Rexin-G for chemotherapy-resistent sarcoma and osteosarcoma. Mol Ther 2009; 17: 1651–7.
   Google Scholar